Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU AI Act Legal Deep-Dive Part 2: Balancing Medtech Innovation With Safety

Executive Summary

The EU AI Act could introduce rigorous regulatory requirements for AI-based medical devices in addition to those contained in the MDR/IVDR. Lawyers from Cooley LLP tell Medtech Insight how changes to the commission’s proposal could improve its impact on medtech while keeping patients safe.

You may also be interested in...



MedTech Forum 2023: Are Attitudes Shifting In Favor Of The EU AI Act?

The proposed EU AI Act has been challenged by industry in recent years, but views expressed during a panel discussion at the MedTech Forum 2023 point towards increasing support among medtech stakeholders for the landmark legislation.

EU AI Act Proposal Adopted By Parliament In Landslide Plenary Vote

The European Commission’s proposed Artificial Intelligence Act is now set to enter high-level negotiations after MEPs voted overwhelmingly in favor of the draft text in a plenary vote.

EU AI Act Legal Deep-Dive Part 1: What Can Medtech Expect, And When?

The text of the European Commission’s proposed AI Act is expected to enter the EU high-level negotiation stage within weeks, yet many questions remain as to what the final regulation will entail. Lawyers from Cooley LLP tell Medtech Insight why considerable changes to the text are possible, and what the new law is likely to mean for medtech.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel